Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH
Key facts
- Who runs it
- University of California, San Francisco
- Where
- San Francisco, United StatesSee the 2 sites
- Trial code
- Status
- Completed
- People taking part
- 14 people enrolled
- Started
- 4 Jan 2021
- Ended
- 31 Jul 2024
- Type of study
- Interventional, 3 groups
- Treatments tested
- Electronic Cigarette
- Record updated
- 15 July 2025
Who can take part
- Age
- 21 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 53 criteriaShow less
Who can take part
- Heart rate < 105 beats per minute (BPM)*
- Systolic Blood pressure <160 and > 90*
- Diastolic Blood Pressure <100 and > 50*
- Body Mass Index (BMI) < 38.0 (at investigator's discretion for higher BMI if no other concurrent health issues); *considered out of range if both machine and manual readings are above/below these thresholds
- Use e-cigarettes on at least 15 days in the past 30 for at least 3 months
- Smoke 10 or fewer cigarettes/tobacco products per day in the last 30 days
- Willing to use mod e-cigarette
- Willing to abstain from tobacco product use for night before study
- Age: > 21 years old and < 70 years old
- Using e-liquid > 0mg/ml nicotine
- Saliva cotinine of ≥ 30 ng/ml or NicAlert=6 (in cases where lab turn around time will delay study procedure)
Who cannot take part
- High Blood Pressure (taking sympatholytic medications such as alpha and beta blockers)
- Drug/Alcohol Dependence
- Alcohol or illicit drug dependence within the past 12 months with the exception of those who have recently completed an alcohol/drug treatment program
- Positive toxicology test at the screening visit (THC \& prescribed medications okay)
- Opioid replacement therapy (including methadone, buprenorphine, or other)
- Medications
- Use of medications that are inducers of nicotine metabolizing enzyme CYP2A4 (Example: rifampicin, carbamazepine, phenobarbital, and other anticonvulsant drugs)
- Concurrent use of nicotine-containing medications
- Concurrent participation in another clinical trial
- Seizures
- Cancer
- Hepatitis B or C or Liver Disease
- Heart disease
- Kidney disease or urinary retention
- Diabetes
- History of stroke
- An ulcer in the past year
- Thyroid disease (okay if controlled with medication)
- Active use of an inhaler for asthma or Chronic Obstructive Pulmonary Disease (COPD)
- Psychiatric conditions
- Current or past schizophrenia, and/or current or past bipolar disorder
- Major personality disorder
- Participants with current or past minor or moderate depression and/or anxiety disorders will be reviewed by the study physician and considered for inclusion
- History of psychiatric hospitalizations are not exclusionary, but study participation will be determined as per study physician's approval
- Psychiatric medications
- Current regular use of any psychiatric medications with the exception of Selective Serotonin Reuptake Inhibitor (SSRI) and serotonin-norepinephrine reuptake Inhibitor (SNRIs) and current evaluation by the study physician that the participant is otherwise healthy, stable, and able to participate
- Any stimulant medications (example: Adderall) generally given for Attention deficit hyperactivity disorder (ADHD) treatment
- Use of sympatholytic medications that affect cardiovascular conditions including hypertension, (Example: beta and alpha-blockers)
- Other/Misc. Chronic Health Conditions
- Other "life threatening illnesses" as per study physician's discretion
- Oral Thrush
- Glaucoma
- Major depression, current or within the past year
- Recent onset or change in cough, fever and/or abdominal symptoms (vomiting or pain) in the past two weeks. (If yes, participant can re-screen when symptoms resolve)
- Positive urine cannabis is not exclusionary but participant must report use of cannabis and agree to abstain from cannabis use for the duration of the study
- Fainting (within the last 30 days)
- Pregnancy
- Pregnancy (self-reported and urine pregnancy test)
- Breastfeeding (determined by self-report)
- Inability to communicate in English
- Planning to quit vaping within the next 60 days
- Uncomfortable with getting blood drawn
Where in United States
- University of California San FranciscoSan Francisco, United States
- Zuckerberg San Francisco General HospitalSan Francisco, United States
About the trial
What the trial wants to find out
This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim is to determine the impact of e-cigarette pH levels on nicotine pharmacology, systemic exposure to toxic volatile organic compounds (VOCs), and short-term cardiovascular effects.
The 3 groups in the trial
- E-liquid pH 5, 7, or 9Other group
Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of 3 assigned e-liquid pH.
Treatment: Electronic Cigarette
- 1 of the other 2 remaining e-liquid pHOther group
Using an electronic cigarette, the participant will complete a standardized vaping session using 1 of the other 2 assigned e-liquid pH.
Treatment: Electronic Cigarette
- Remaining e-liquid pHOther group
Using an electronic cigarette, the participant will complete a standardized vaping session using the remaining assigned e-liquid pH.
Treatment: Electronic Cigarette
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 15 July 2025